Bright light therapy in Parkinson's disease: a pilot study.

by Sebastian Paus, Tanja Schmitz-Hübsch, Ullrich Wüllner, Antje Vogel, Thomas Klockgether, Michael Abele
Movement disorders : official journal of the Movement Disorder Society ()


Several observations suggest a beneficial effect of melatonin antagonism for Parkinson's disease (PD). Although bright light therapy (BLT) suppresses melatonin release and is an established treatment for depression and sleep disturbances, it has not been evaluated in PD. We examined effects of BLT on motor symptoms, depression, and sleep in PD in a randomized placebo-controlled double-blind study in 36 PD patients, using Parkinson's Disease Rating Scale (UPDRS) I-IV, Beck's Depression Inventory, and Epworth Sleepiness Scale. All patients received BLT for 15 days in the morning, 30 min daily. Illuminance was 7.500 lux in the active treatment group and 950 lux in the placebo group. Although group differences were small, BLT led to significant improvement of tremor, UPDRS I, II, and IV, and depression in the active treatment group but not in the placebo group. It was very well tolerated. Follow up studies in more advanced patient populations employing longer treatment durations are warranted.

Cite this document (BETA)

Readership Statistics

17 Readers on Mendeley
by Discipline
by Academic Status
24% Student (Bachelor)
18% Student (Postgraduate)
12% Ph.D. Student
by Country
12% United States
6% Germany

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Sign up & Download

Already have an account? Sign in